No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
NBIX240816C120000
- 28.00
- -0.50-1.75%
15min DelayClose Jul 22 10:40 ET
28.00High28.00Low
28.00Open28.50Pre Close4 Volume6 Open Interest120.00Strike Price11.20KTurnover57.46%IV1.87%PremiumAug 16, 2024Expiry Date25.28Intrinsic Value100Multiplier25DDays to Expiry2.72Extrinsic Value100Contract SizeAmericanOptions Type0.9133Delta0.0072Gamma5.45Leverage Ratio-0.0833Theta0.0737Rho4.98Eff Leverage0.0605Vega
Intraday
- 5D
- Daily
News
These 4 Measures Indicate That Neurocrine Biosciences (NASDAQ:NBIX) Is Using Debt Safely
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you
S&P 500 Futures Climb In Premarket Trading; Neurocrine Biosciences, Equitable Holdings Lead
This article was automatically generated by Barrons.com using technology from Automated Insights. With U.S. stock markets set to open in two hours, Neurocrine Biosciences Inc. (NBIX) was up 8.8% in
Express News | Neurocrine Biosciences Inc : BMO Raises Target Price to $142 From $138
Neurocrine Biosciences Rolls Out Ingrezza Sprinkle Capsules to Treat Tardive Dyskinesia, Chorea With Huntington's Disease
Neurocrine Biosciences (NBIX) said Thursday it has launched a new sprinkle formulation of Ingrezza capsules to treat adults with tardive dyskinesia and chorea associated with Huntington's disease, a
Express News | Neurocrine Biosciences Launches INGREZZA SPRINKLE Capsules
Express News | Neurocrine Biosciences Launches Ingrezza® Sprinkle (Valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing
Comments
🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics(IOVA.US$ Phase 2
$Supernus Pharmaceuticals(SUPN.US$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US$ Phase 2a
$MorphoSys(MOR.US$ Phase 2
$Nuvation Bio(NUVB.US$ Phase 2
$ALX Oncology(ALXO.US$ Phase 2
$BioXcel Therapeutics(BTAI.US$ Phase 2
$Purple Biotech(PPBT.US$ Phase 2
$Arcus Biosciences(RCUS.US$ Phase 2
$Medicenna Therapeutics(MDNAF.US$ Phase 2b
$Affimed NV(AFMD.US$ Phase 2
$Barinthus Biotherapeutics(BRNS.US$ Phase 2b...
$Iovance Biotherapeutics(IOVA.US$ Phase 2
$Supernus Pharmaceuticals(SUPN.US$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US$ Phase 2a
$MorphoSys(MOR.US$ Phase 2
$Nuvation Bio(NUVB.US$ Phase 2
$ALX Oncology(ALXO.US$ Phase 2
$BioXcel Therapeutics(BTAI.US$ Phase 2
$Purple Biotech(PPBT.US$ Phase 2
$Arcus Biosciences(RCUS.US$ Phase 2
$Medicenna Therapeutics(MDNAF.US$ Phase 2b
$Affimed NV(AFMD.US$ Phase 2
$Barinthus Biotherapeutics(BRNS.US$ Phase 2b...
13
3
» Holdings: 112
» Holdings in Top 20: 58.46%
» Qtr over Qtr Change**: 28.47%
Top Holdings:
$Cerevel Therapeutics Holdings(CERE.US$
$Amicus Therapeutics(FOLD.US$
$Iovance Biotherapeutics(IOVA.US$
$Arcellx(ACLX.US$
$Nuvalent(NUVL.US$
$Apogee Therapeutics(APGE.US$
$Inhibrx(INBX.US$
$Fusion Pharmaceuticals(FUSN.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Vaxcyte(PCVX.US$
$Soleno Therapeutics(SLNO.US$
$Medtronic(MDT.US$
$Madrigal Pharmaceuticals(MDGL.US$
...
» Holdings in Top 20: 58.46%
» Qtr over Qtr Change**: 28.47%
Top Holdings:
$Cerevel Therapeutics Holdings(CERE.US$
$Amicus Therapeutics(FOLD.US$
$Iovance Biotherapeutics(IOVA.US$
$Arcellx(ACLX.US$
$Nuvalent(NUVL.US$
$Apogee Therapeutics(APGE.US$
$Inhibrx(INBX.US$
$Fusion Pharmaceuticals(FUSN.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Vaxcyte(PCVX.US$
$Soleno Therapeutics(SLNO.US$
$Medtronic(MDT.US$
$Madrigal Pharmaceuticals(MDGL.US$
...
8
See summary 👇
📣 4 PDUFAs upcoming in May:
$Dynavax Technologies(DVAX.US$ : 🤔
⇒ Heplisav-B
‣ vaccination of adults on hemodialysis
‣ PDUFA date: 5/13/24 (sBLA)
$Ascendis Pharma A/S(ASND.US$ : 🤔
⇒ YORVIPATH®
‣ hypoparathyroidism
‣ PDUFA date: 5/14/24 (NDA)
$Bristol-Myers Squibb(BMY.US$ : 🤔
⇒ Breyanzi®
‣ PDUFA dates: (sBLAs)
‣‣ 5/23/24 (r/r follicular lymphoma)
‣‣ 5/31/24 (r/r mantle cell lymphoma)
🗓️ Last week’s PDUFAs:
$X4 Pharmaceuticals(XFOR.US$ : Approved 4/29 🎉
⇨ XOLREMDI (mavorixafor)
‣ WHI...
📣 4 PDUFAs upcoming in May:
$Dynavax Technologies(DVAX.US$ : 🤔
⇒ Heplisav-B
‣ vaccination of adults on hemodialysis
‣ PDUFA date: 5/13/24 (sBLA)
$Ascendis Pharma A/S(ASND.US$ : 🤔
⇒ YORVIPATH®
‣ hypoparathyroidism
‣ PDUFA date: 5/14/24 (NDA)
$Bristol-Myers Squibb(BMY.US$ : 🤔
⇒ Breyanzi®
‣ PDUFA dates: (sBLAs)
‣‣ 5/23/24 (r/r follicular lymphoma)
‣‣ 5/31/24 (r/r mantle cell lymphoma)
🗓️ Last week’s PDUFAs:
$X4 Pharmaceuticals(XFOR.US$ : Approved 4/29 🎉
⇨ XOLREMDI (mavorixafor)
‣ WHI...
7
2
📣 3 PDUFAs left in April! See summary 👇
🗓️ Last week’s PDUFAs:
$Pfizer(PFE.US$ : Approved 4/26 🎉
⇨ BEQVEZ (fidanacogene elaparvovec-dzkt)
▹ Hemophilia B
▹ BLA
▹ PDUFA date: Q2 2024
$Day One Biopharmaceuticals(DAWN.US$ : Approved 4/23 🎉
⇨ OJEMDA (tovorafenib)
▹ Pediatric low-grade glioma
▹ NDA
▹ PDUFA date: 4/30/24
$ImmunityBio(IBRX.US$ : Approved 4/22 🎉
⇨ Anktiva + BCG
▹ Bladder cancer
▹ resubmitted BLA
▹ PDUFA date: 4/23/24
$Abeona Therapeutics(ABEO.US$ : CRL 4/22 🙁
⚠...
🗓️ Last week’s PDUFAs:
$Pfizer(PFE.US$ : Approved 4/26 🎉
⇨ BEQVEZ (fidanacogene elaparvovec-dzkt)
▹ Hemophilia B
▹ BLA
▹ PDUFA date: Q2 2024
$Day One Biopharmaceuticals(DAWN.US$ : Approved 4/23 🎉
⇨ OJEMDA (tovorafenib)
▹ Pediatric low-grade glioma
▹ NDA
▹ PDUFA date: 4/30/24
$ImmunityBio(IBRX.US$ : Approved 4/22 🎉
⇨ Anktiva + BCG
▹ Bladder cancer
▹ resubmitted BLA
▹ PDUFA date: 4/23/24
$Abeona Therapeutics(ABEO.US$ : CRL 4/22 🙁
⚠...
11
4
Read more
The Real Wojak : Do you have like a top 3-5 that you like more than all the other ones? This list is way too long
72991267 : Glad I have some $Candel Therapeutics (CADL.US)$ after my disastrous SBFM.
Rana Hasan1 : List too long